hydroxychloroquine has been researched along with Cardiomyopathies in 38 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Cardiomyopathies: A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The recent empirical use of hydroxychloroquine (HCQ) in coronavirus disease 2019 (COVID-19) revived the interest in its cardiac toxicity, increasingly sidelined over time." | 8.02 | Insights on the Evidence of Cardiotoxicity of Hydroxychloroquine Prior and During COVID-19 Epidemic. ( Drici, MD; Fresse, A; Gérard, A; Micallef, J; Rocher, F; Romani, S; Van-Obberghen, É; Viard, D, 2021) |
| " Two years prior to admission to our hospital, she had been diagnosed with rheumatoid arthritis and treated with hydroxychloroquine (HCQ) with a cumulative dose of 164 g." | 7.78 | Hydroxychloroquine-induced cardiomyopathy that presented as pulmonary hypertension: a newly noted complication. ( Bae, SM; Chin, JY; Ihm, SM; Jung, HO; Kim, JJ; Kim, TS; Lee, KY; Park, SH; Youn, HJ, 2012) |
| "Hydroxychloroquine is a disease-modifying antirheumatic drug used for various rheumatological conditions." | 5.91 | Endomyocardial biopsy-proven hydroxychloroquine-induced cardiomyopathy in a patient with rheumatoid arthritis. ( Dalia, T; Malhotra, A; Pathak, MA; Vidic, A, 2023) |
| " Hydroxychloroquine and its predecessor chloroquine are medications commonly used in the treatment of systemic lupus erythematosus, rheumatoid arthritis, and other connective tissue disorders." | 4.90 | Hydroxychloroquine-induced cardiomyopathy: case report, pathophysiology, diagnosis, and treatment. ( Cujec, B; Oudit, GY; Paterson, DI; Putko, BN; Ringrose, J; Tien, J; Yogasundaram, H, 2014) |
| "The recent empirical use of hydroxychloroquine (HCQ) in coronavirus disease 2019 (COVID-19) revived the interest in its cardiac toxicity, increasingly sidelined over time." | 4.02 | Insights on the Evidence of Cardiotoxicity of Hydroxychloroquine Prior and During COVID-19 Epidemic. ( Drici, MD; Fresse, A; Gérard, A; Micallef, J; Rocher, F; Romani, S; Van-Obberghen, É; Viard, D, 2021) |
| " Two years prior to admission to our hospital, she had been diagnosed with rheumatoid arthritis and treated with hydroxychloroquine (HCQ) with a cumulative dose of 164 g." | 3.78 | Hydroxychloroquine-induced cardiomyopathy that presented as pulmonary hypertension: a newly noted complication. ( Bae, SM; Chin, JY; Ihm, SM; Jung, HO; Kim, JJ; Kim, TS; Lee, KY; Park, SH; Youn, HJ, 2012) |
| " However, some of these medications have potential cardiac adverse effects." | 2.66 | Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol. ( Lazar, S; Naksuk, N; Peeraphatdit, TB, 2020) |
| "Hydroxychloroquine is a disease-modifying antirheumatic drug used for various rheumatological conditions." | 1.91 | Endomyocardial biopsy-proven hydroxychloroquine-induced cardiomyopathy in a patient with rheumatoid arthritis. ( Dalia, T; Malhotra, A; Pathak, MA; Vidic, A, 2023) |
| "Danon disease is a lethal X-linked genetic syndrome resulting from radical mutations in the LAMP2 gene." | 1.72 | Autophagy guided interventions to modify the cardiac phenotype of Danon disease. ( Abraham, NG; Alcalai, R; Arad, M; Hochhauser, E; Petrover, Z; Seidman, CE; Seidman, J; Shainberg, A; Waldman, M; Yadin, D, 2022) |
| "A 72-year-old woman with systemic lupus erythematosus treated for 24 years by HCQ received a kidney allograft." | 1.62 | [Toxic hydroxychloroquine-induced cardiomyopathy complicating systemic lupus treatment]. ( Bories, MC; Bruneval, P; Gibault, L; Tharaux, PL, 2021) |
| "One objective in the treatment of systemic lupus erythematosus (SLE) disease activity is to reduce long-term rates of organ damage." | 1.48 | Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort. ( Magder, LS; Petri, M, 2018) |
| "The first case, in a patient with systemic lupus erythematosus, was found to have megamitochondria in addition to myelin figures seen by electron microscopy." | 1.34 | New clinical and ultrastructural findings in hydroxychloroquine-induced cardiomyopathy--a report of 2 cases. ( Barouch, LA; Champion, HC; Halushka, MK; Soong, TR; Wigley, FM, 2007) |
| "A 39-year-old woman with a history of systemic lupus erythematosus developed chest pain and conduction abnormalities." | 1.33 | Hydroxychloroquine-induced cardiotoxicity in a 39-year-old woman with systemic lupus erythematosus and systolic dysfunction. ( Amin, S; Bhatia, S; Edwards, WD; Keating, RJ; Sinak, LJ; Williams, A, 2005) |
| "Prednisone was used at a starting dose from about 0." | 1.33 | Muscle involvement in sarcoidosis: a retrospective and followup studies. ( Bardin, T; Berenbaum, F; Fayad, F; Lioté, F; Orcel, P, 2006) |
| "Chloroquine is a neuromyotoxin that affects nerves and cardiac and skeletal muscles." | 1.27 | Chloroquine neuromyotoxicity. Clinical and pathologic perspective. ( Chou, SM; Estes, ML; Ewing-Wilson, D; Hanson, M; Mitsumoto, H; Ratliff, NB; Shirey, E, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (7.89) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (10.53) | 29.6817 |
| 2010's | 16 (42.11) | 24.3611 |
| 2020's | 15 (39.47) | 2.80 |
| Authors | Studies |
|---|---|
| Yadin, D | 1 |
| Petrover, Z | 1 |
| Shainberg, A | 1 |
| Alcalai, R | 1 |
| Waldman, M | 1 |
| Seidman, J | 1 |
| Seidman, CE | 1 |
| Abraham, NG | 1 |
| Hochhauser, E | 1 |
| Arad, M | 1 |
| Braunstein, ED | 3 |
| Olshan, DS | 3 |
| Gabriels, JK | 3 |
| Shaikh, Z | 3 |
| Lerman, BB | 3 |
| Cheung, JW | 3 |
| Malhotra, A | 1 |
| Pathak, MA | 1 |
| Dalia, T | 1 |
| Vidic, A | 1 |
| Abbi, B | 1 |
| Patel, S | 1 |
| Kumthekar, A | 1 |
| Schwartz, D | 1 |
| Blanco, I | 1 |
| Hanneman, K | 1 |
| Alberdi, HV | 1 |
| Karur, GR | 1 |
| Tselios, K | 2 |
| Harvey, PJ | 1 |
| Gladman, DD | 2 |
| Akhtari, S | 1 |
| Osuntokun, T | 1 |
| Wald, RM | 1 |
| Thavendiranathan, P | 1 |
| Butany, J | 2 |
| Urowitz, MB | 2 |
| Layoun, ME | 1 |
| Desmarais, J | 1 |
| Heitner, SB | 1 |
| Masri, A | 1 |
| El Boussadani, B | 1 |
| Benajiba, C | 1 |
| Aajal, A | 1 |
| Ait Brik, A | 1 |
| Ammour, O | 1 |
| El Hangouch, J | 1 |
| Oussama, O | 1 |
| Oussama, B | 1 |
| Tahiri, N | 1 |
| Raissuni, Z | 1 |
| Juusela, A | 1 |
| Nazir, M | 1 |
| Gimovsky, M | 1 |
| Naksuk, N | 1 |
| Lazar, S | 1 |
| Peeraphatdit, TB | 1 |
| Khalaf, S | 1 |
| Khan, N | 1 |
| Al-Mallah, M | 1 |
| Kassi, M | 1 |
| Shah, D | 1 |
| Wille, F | 1 |
| Birkmeier, S | 1 |
| Tiemann, K | 1 |
| Lewalter, T | 1 |
| Klingel, K | 1 |
| Rabe, C | 1 |
| Sick, P | 1 |
| Kuraitis, D | 1 |
| Murina, A | 1 |
| Romani, S | 1 |
| Gérard, A | 1 |
| Fresse, A | 1 |
| Viard, D | 1 |
| Van-Obberghen, É | 1 |
| Micallef, J | 1 |
| Rocher, F | 1 |
| Drici, MD | 1 |
| Nadeem, U | 1 |
| Raafey, M | 1 |
| Kim, G | 1 |
| Treger, J | 1 |
| Pytel, P | 1 |
| N Husain, A | 1 |
| Schulte, JJ | 1 |
| Bories, MC | 1 |
| Gibault, L | 1 |
| Tharaux, PL | 1 |
| Bruneval, P | 1 |
| Dogar, MU | 1 |
| Shah, NN | 1 |
| Ishtiaq, S | 1 |
| Shah, PN | 1 |
| Shah, P | 1 |
| Mathew, S | 1 |
| Vittorio, TJ | 1 |
| Petri, M | 1 |
| Magder, LS | 1 |
| Dobranici, M | 1 |
| Tocitu, A | 1 |
| Delcea, C | 1 |
| Dan, GA | 1 |
| Sandhu, VK | 1 |
| Weisman, MH | 2 |
| Daniels, BH | 1 |
| McComb, RD | 1 |
| Mobley, BC | 2 |
| Gultekin, SH | 2 |
| Lee, HS | 1 |
| Margeta, M | 1 |
| Yogasundaram, H | 1 |
| Putko, BN | 1 |
| Tien, J | 1 |
| Paterson, DI | 1 |
| Cujec, B | 1 |
| Ringrose, J | 1 |
| Oudit, GY | 1 |
| Chatre, C | 1 |
| Filippi, N | 1 |
| Roubille, F | 1 |
| Pers, YM | 1 |
| Harvey, P | 1 |
| Mak, S | 1 |
| Chantal, M | 1 |
| Abdin, A | 1 |
| Pöss, J | 1 |
| Kandolf, R | 1 |
| Thiele, H | 1 |
| Muthukrishnan, P | 1 |
| Roukoz, H | 1 |
| Grafton, G | 1 |
| Jessurun, J | 1 |
| Colvin-Adams, M | 1 |
| Newton-Cheh, C | 1 |
| Lin, AE | 1 |
| Baggish, AL | 1 |
| Wang, H | 1 |
| Frustaci, A | 1 |
| Morgante, E | 1 |
| Antuzzi, D | 1 |
| Russo, MA | 1 |
| Chimenti, C | 1 |
| Abbasi, S | 1 |
| Tarter, L | 1 |
| Farzaneh-Far, R | 1 |
| Farzaneh-Far, A | 1 |
| Sumpter, MD | 1 |
| Tatro, LS | 1 |
| Stoecker, WV | 1 |
| Rader, RK | 1 |
| Azimian, M | 1 |
| Hata, JL | 1 |
| Atkinson, JB | 1 |
| Ely, KA | 1 |
| Fuchs, HA | 1 |
| Bae, SM | 1 |
| Jung, HO | 1 |
| Ihm, SM | 1 |
| Kim, JJ | 1 |
| Chin, JY | 1 |
| Kim, TS | 1 |
| Park, SH | 1 |
| Youn, HJ | 1 |
| Lee, KY | 1 |
| Nord, JE | 1 |
| Shah, PK | 1 |
| Rinaldi, RZ | 1 |
| Keating, RJ | 1 |
| Bhatia, S | 1 |
| Amin, S | 1 |
| Williams, A | 1 |
| Sinak, LJ | 1 |
| Edwards, WD | 1 |
| Fayad, F | 1 |
| Lioté, F | 1 |
| Berenbaum, F | 1 |
| Orcel, P | 1 |
| Bardin, T | 1 |
| Soong, TR | 1 |
| Barouch, LA | 1 |
| Champion, HC | 1 |
| Wigley, FM | 1 |
| Halushka, MK | 1 |
| Ratliff, NB | 2 |
| Estes, ML | 2 |
| Myles, JL | 1 |
| Shirey, EK | 1 |
| McMahon, JT | 1 |
| Ewing-Wilson, D | 1 |
| Chou, SM | 1 |
| Mitsumoto, H | 1 |
| Hanson, M | 1 |
| Shirey, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Trial of Efficacy and Safety of an Early OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome: a Strategy to Prevent Hospitalization[NCT04365582] | Phase 3 | 0 participants (Actual) | Interventional | 2020-05-07 | Withdrawn (stopped due to The PI decided.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for hydroxychloroquine and Cardiomyopathies
| Article | Year |
|---|---|
[COVID-19 pandemia: Impact on the cariovascular system. Data of 1
Topics: Antimalarials; Antiviral Agents; Azithromycin; Betacoronavirus; Cardiomyopathies; Cardiovascular Dis | 2020 |
Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol.
Topics: Anti-Bacterial Agents; Antibodies, Monoclonal; Antimalarials; Arrhythmias, Cardiac; Betacoronavirus; | 2020 |
Chloroquine- and Hydroxychloroquine-Induced Cardiomyopathy: A Case Report and Brief Literature Review.
Topics: Antimalarials; Antiviral Agents; Cardiomyopathies; Chloroquine; COVID-19; COVID-19 Drug Treatment; H | 2021 |
Hydroxychloroquine-induced cardiomyopathy: case report, pathophysiology, diagnosis, and treatment.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biopsy; Cardiomyopathies; Electrocardiography; Female; | 2014 |
Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of the literature.
Topics: Adult; Antirheumatic Agents; Cardiomyopathies; Female; Heart; Heart Conduction System; Humans; Hydro | 2004 |
33 other studies available for hydroxychloroquine and Cardiomyopathies
| Article | Year |
|---|---|
Autophagy guided interventions to modify the cardiac phenotype of Danon disease.
Topics: Animals; Autophagy; Bortezomib; Cardiomegaly; Cardiomyopathies; Glycogen Storage Disease Type IIb; H | 2022 |
Hydroxychloroquine-Associated Cardiomyopathy With Midmyocardial Right Ventricular Tachycardia.
Topics: Arrhythmias, Cardiac; Cardiomyopathies; Heart Ventricles; Humans; Hydroxychloroquine; Tachycardia, V | 2022 |
Hydroxychloroquine-Associated Cardiomyopathy With Midmyocardial Right Ventricular Tachycardia.
Topics: Arrhythmias, Cardiac; Cardiomyopathies; Heart Ventricles; Humans; Hydroxychloroquine; Tachycardia, V | 2022 |
Hydroxychloroquine-Associated Cardiomyopathy With Midmyocardial Right Ventricular Tachycardia.
Topics: Arrhythmias, Cardiac; Cardiomyopathies; Heart Ventricles; Humans; Hydroxychloroquine; Tachycardia, V | 2022 |
Hydroxychloroquine-Associated Cardiomyopathy With Midmyocardial Right Ventricular Tachycardia.
Topics: Arrhythmias, Cardiac; Cardiomyopathies; Heart Ventricles; Humans; Hydroxychloroquine; Tachycardia, V | 2022 |
Hydroxychloroquine-Associated Cardiomyopathy With Midmyocardial Right Ventricular Tachycardia.
Topics: Arrhythmias, Cardiac; Cardiomyopathies; Heart Ventricles; Humans; Hydroxychloroquine; Tachycardia, V | 2022 |
Hydroxychloroquine-Associated Cardiomyopathy With Midmyocardial Right Ventricular Tachycardia.
Topics: Arrhythmias, Cardiac; Cardiomyopathies; Heart Ventricles; Humans; Hydroxychloroquine; Tachycardia, V | 2022 |
Hydroxychloroquine-Associated Cardiomyopathy With Midmyocardial Right Ventricular Tachycardia.
Topics: Arrhythmias, Cardiac; Cardiomyopathies; Heart Ventricles; Humans; Hydroxychloroquine; Tachycardia, V | 2022 |
Hydroxychloroquine-Associated Cardiomyopathy With Midmyocardial Right Ventricular Tachycardia.
Topics: Arrhythmias, Cardiac; Cardiomyopathies; Heart Ventricles; Humans; Hydroxychloroquine; Tachycardia, V | 2022 |
Hydroxychloroquine-Associated Cardiomyopathy With Midmyocardial Right Ventricular Tachycardia.
Topics: Arrhythmias, Cardiac; Cardiomyopathies; Heart Ventricles; Humans; Hydroxychloroquine; Tachycardia, V | 2022 |
Endomyocardial biopsy-proven hydroxychloroquine-induced cardiomyopathy in a patient with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Biopsy; Cardiac Catheterization; Cardiomyopathies; Female; Heart Failure; Hum | 2023 |
A Case of Cardiomyopathy With Long-term Hydroxychloroquine Use.
Topics: Antirheumatic Agents; Cardiomyopathies; Humans; Hydroxychloroquine | 2020 |
Antimalarial-Induced Cardiomyopathy Resembles Fabry Disease on Cardiac MRI.
Topics: Adult; Aged; Antimalarials; Biopsy; Cardiomyopathies; Cardiotoxicity; Chloroquine; Diagnosis, Differ | 2020 |
Hot hearts on bone scintigraphy are not all amyloidosis: hydroxychloroquine-induced restrictive cardiomyopathy.
Topics: Amyloidosis; Cardiomyopathies; Cardiomyopathy, Restrictive; Humans; Hydroxychloroquine; Radionuclide | 2020 |
Two cases of coronavirus 2019-related cardiomyopathy in pregnancy.
Topics: Adult; Anti-Arrhythmia Agents; Antibodies, Monoclonal, Humanized; Anticonvulsants; Blood Gas Analysi | 2020 |
A positive PYP scan: Thinking beyond amyloid.
Topics: Antirheumatic Agents; Cardiomyopathies; Cardiotoxicity; Female; Humans; Hydroxychloroquine; Lupus Er | 2021 |
[Proximal myopathy and fulminant heart failure in a 57 year-old female patient with lupus erythematosus].
Topics: Biopsy; Cardiomyopathies; Echocardiography; Fatal Outcome; Female; Heart; Heart Failure; Humans; Hyd | 2020 |
Facts, not Fear: Safety of Hydroxychloroquine.
Topics: Acute Generalized Exanthematous Pustulosis; Agranulocytosis; Anemia, Aplastic; Antirheumatic Agents; | 2020 |
Insights on the Evidence of Cardiotoxicity of Hydroxychloroquine Prior and During COVID-19 Epidemic.
Topics: Adult; Aged; Cardiomyopathies; Cardiotoxicity; COVID-19 Drug Treatment; Female; Heart Conduction Sys | 2021 |
[Toxic hydroxychloroquine-induced cardiomyopathy complicating systemic lupus treatment].
Topics: Aged; Biopsy; Cardiomyopathies; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic | 2021 |
Hydroxychloroquine-induced restrictive cardiomyopathy: a case report.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biopsy; Cardiomyopathies; Cardiotoxicity; Disease Progr | 2018 |
Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort.
Topics: Adult; Antirheumatic Agents; Cardiomyopathies; Cataract; Cohort Studies; Diabetes Mellitus; Disease | 2018 |
Left Ventricular noncompaction in a patient with systemic lupus erythematosus.
Topics: Adrenal Cortex Hormones; Cardiomyopathies; Echocardiography; Electrocardiography; Female; Humans; Hy | 2019 |
Hydroxychloroquine - How Much Is Too Much?
Topics: Antimalarials; Cardiomyopathies; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Personal | 2019 |
LC3 and p62 as diagnostic markers of drug-induced autophagic vacuolar cardiomyopathy: a study of 3 cases.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antimalarials; Autophagy; Biomarkers; Cardiomyopa | 2013 |
Heart Involvement in a Woman Treated with Hydroxychloroquine for Systemic Lupus Erythematosus Revealing Fabry Disease.
Topics: Biopsy, Needle; Cardiomyopathies; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Ad | 2016 |
Hydroxychloroquine-Induced Cardiomyopathy in Systemic Lupus Erythematosus.
Topics: Aged; Antimalarials; Cardiomyopathies; Disease Progression; Echocardiography; Female; Humans; Hydrox | 2016 |
Hydroxychloroquine-induced cardiomyopathy in a patient with limited cutaneous systemic sclerosis.
Topics: Antirheumatic Agents; Cardiomyopathies; Echocardiography; Female; Humans; Hydroxychloroquine; Magnet | 2017 |
Hydroxychloroquine-induced cardiomyopathy: a case report.
Topics: Biopsy; Cardiac Resynchronization Therapy; Cardiomyopathies; Cardiovascular Agents; Defibrillators, | 2011 |
Case records of the Massachusetts General Hospital. Case 11-2011. A 47-year-old man with systemic lupus erythematosus and heart failure.
Topics: Antirheumatic Agents; Biomarkers; Cardiomyopathies; Diagnosis, Differential; Echocardiography; Elect | 2011 |
Inhibition of cardiomyocyte lysosomal activity in hydroxychloroquine cardiomyopathy.
Topics: Adult; Cardiomyopathies; Enzyme Inhibitors; Humans; Hydrolases; Hydroxychloroquine; Lysosomes; Male; | 2012 |
Hydroxychloroquine: a treatable cause of cardiomyopathy.
Topics: Antirheumatic Agents; Biopsy; Cardiomyopathies; Coronary Angiography; Diagnosis, Differential; Dyspn | 2012 |
Evidence for risk of cardiomyopathy with hydroxychloroquine.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Cardiomyopathies; Dose- | 2012 |
Fatal antimalarial-induced cardiomyopathy: report of 2 cases.
Topics: Adult; Antimalarials; Arthritis, Rheumatoid; Cardiomyopathies; Chloroquine; Fatal Outcome; Female; H | 2012 |
Hydroxychloroquine-induced cardiomyopathy that presented as pulmonary hypertension: a newly noted complication.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cardiac Catheterization; Cardiomyopathies; Female; Huma | 2012 |
Hydroxychloroquine-induced cardiotoxicity in a 39-year-old woman with systemic lupus erythematosus and systolic dysfunction.
Topics: Cardiomyopathies; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Middle Aged; Ve | 2005 |
Muscle involvement in sarcoidosis: a retrospective and followup studies.
Topics: Adult; Cardiomyopathies; Chronic Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studie | 2006 |
New clinical and ultrastructural findings in hydroxychloroquine-induced cardiomyopathy--a report of 2 cases.
Topics: Aged; Antirheumatic Agents; Cardiomyopathies; Female; Humans; Hydroxychloroquine; Lupus Erythematosu | 2007 |
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 38-1988. A 58-year-old woman with fever, sweats, congestive heart failure, and lymphadenopathy after treatment for a diagnosis of systemic lupus erythematosus.
Topics: Bone Marrow; Cardiomyopathies; Diagnosis, Differential; Female; Hodgkin Disease; Humans; Hydroxychlo | 1988 |
Diagnosis of chloroquine cardiomyopathy by endomyocardial biopsy.
Topics: Biopsy; Cardiomyopathies; Chloroquine; Endocardium; Female; Humans; Hydroxychloroquine; Lupus Erythe | 1987 |
Chloroquine neuromyotoxicity. Clinical and pathologic perspective.
Topics: Aged; Biopsy; Cardiomyopathies; Chloroquine; Female; Humans; Hydroxychloroquine; Male; Middle Aged; | 1987 |